Announcing a new article publication for Cardiovascular Innovations and Applications journal. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are approved for heart failure with reduced ejection fraction (HFrEF).
Irish biotech collects $75M in Series B to start Phase 3 rare joint tumor trial
SynOx Therapeutics has completed a $75 million Series B raise to advance its monoclonal antibody drug through a registrational trial for a type of non-cancerous